Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
High mobility group box protein 4 (HMGB4) is a mammalian-specific, non-histone chromatin protein and the least characterized member of the HMGB family. Unlike HMGB1–3, it lacks the typical acidic C-terminal tail, contains two HMG box domains, and is primarily expressed in testis and, to a lesser extent, in the brain[3][1][2]. HMGB4 localizes to chromatin and acts as a transcriptional repressor, modulating the expression of genes involved in neuronal and germ cell differentiation and influencing post-translational histone modifications. It binds DNA in a sequence-independent but structure-dependent manner, and is implicated in chromatin organization and gene regulation, especially during spermatogenesis and neuronal development[1][2][3][4][5]. Its expression pattern and functional studies suggest specialized roles in tissue-specific chromatin regulation. No approved drugs or therapeutic compounds directly target HMGB4, and its potential as a clinical biomarker or direct therapeutic target remains unexplored.
Not applicable (no direct drugs known; regulates chromatin accessibility and transcriptional repression[3][1])
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on High mobility group box protein 4 (HMGB4).